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Prostate cancer is the most common cancer in men in United States and the fifth most 
common cancer in men in Korea. Although the majority of patients with metastatic pros-
tate cancer initially respond to androgen deprivation therapy, almost all patients will 
eventually progress to develop castration-resistant prostate cancer (CRPC). Treat-
ment options for CRPC remain limited. Prostate cancer was considered unresponsive 
to chemotherapy until the mid-1990s, when mitoxantrone combined with prednisone 
was shown to play a role in the palliative treatment of patients with CRPC. In 2004, 
two large randomized clinical trials demonstrated for the first time a small but sig-
nificant survival advantage of docetaxel-based chemotherapy compared with mitoxan-
trone in patients with metastatic CRPC. Recently, cabazitaxel was shown to improve 
survival in patients with metastatic CRPC who progressed after docetaxel-based 
chemotherapy. Sipuleucel-T was also demonstrated to improve overall survival in pa-
tients with asymptomatic or minimally symptomatic metastatic CRPC. Along with mi-
toxantrone and docetaxel, cabazitaxel and sipuleucel-T are now approved for use in 
metastatic CRPC by the US Food and Drug Administration. There have been multiple 
early-phase clinical trials of various agents for the treatment of CRPC, and some are 
in phase III development. This review focuses on the key clinical trials of various treat-
ment options of CRPC currently in use and under investigation.
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Prostate cancer is the most common cancer and the second 
most common cause of cancer-related death in men in 
United States [1]. In Korea, the incidence of prostate cancer 
is much lower than in most Western countries. However, 
it has been rapidly increasing recently [2,3]. Prostate can-
cer is now the fifth most common cancer in men in Korea 
[4].
　Since the landmark studies of Huggins and Hodges dem-
onstrated the beneficial effects of surgical castration and 
estrogen administration in patients with metastatic pros-
tate cancer in 1941 [5], androgen deprivation therapy 
(ADT) has been the mainstay of treatment for metastatic 
prostate cancer [6-8]. Although the majority of patients 
with metastatic disease initially respond to ADT, almost 
all patients will eventually progress after an average of 18 
to 24 months, despite maintenance of castrate serum tes-
tosterone levels [9]. This clinical condition has been de-
scribed as androgen-independent or hormone-refractory 
prostate cancer (HRPC). However, these previously used 
terms have largely been replaced with castration-resistant 
prostate cancer (CRPC), with the awareness of the persis-
tent androgen receptor signaling activity despite castrate 
serum testosterone levels [6,8,10-13]. Treatment options 
for CRPC remain limited, and the prognosis of patients 
with CRPC is dismal, with a median survival of 12 to 18 
months [9,10]. This review discusses the treatment options 
of CRPC currently in use and under investigation.Korean J Urol 2011;52:157-165
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SECONDARY HORMONAL MANIPULATIONS
For patients whose disease progresses after maximal an-
drogen blockade (MAB), antiandrogen may be discontinued 
in an attempt to achieve antiandrogen withdrawal response. 
Antiandrogen withdrawal response was initially docu-
mented in patients who discontinued flutamide upon the 
development of CRPC [14]. Antiandrogen withdrawal re-
sponses have also been described in patients treated with 
bicalutamide, nilutamide, megestrol acetate, cyproterone 
acetate, chlormadinone acetate, diethylstilbestrol (DES), 
and 13-cis-retinoic acid. Antiandrogen withdrawal results 
in ≥50% prostate-specific antigen (PSA) reduction in 15% 
to 30% of patients. The duration of response is brief, with 
a median duration of approximately 4 months [9,15-17].
　Antiandrogen may be switched to an alternative anti-
androgen in patients who relapse after initial MAB. In the 
study by Suzuki et al, antiandrogen withdrawal response 
was observed in 15.1% of patients who relapsed after initial 
MAB. Subsequently, second-line MAB was performed by 
switching to an alternative nonsteroidal antiandrogen 
(i.e., bicalutamide to flutamide and vice versa). Overall, ≥
50% and ＜50% PSA reductions were observed in 35.8% 
and 25.4% of patients, respectively, and the overall re-
sponse duration was more than 202 days [18]. Kassouf et 
al reported that 64% of patients treated with nilutamide 
after progression on initial MAB, including flutamide or bi-
calutamide, experienced PSA reduction, and 29% of pa-
tients sustained ＞50% PSA reduction beyond 3 months 
[19].
　High-dose (150 mg daily) bicalutamide as second-line 
hormonal therapy resulted in ≥50% PSA reduction in 20% 
to 45% of patients [20-22]. The most recent study in pa-
tients with nonmetastatic CRPC revealed that the median 
duration of response was 18.5 months in patients with 50% 
to 85% PSA reduction, and 37.4 months in those with ≥85% 
PSA reduction [22].
　Estrogens may exert their effect by suppressing the hy-
pothalamic-pituitary-gonadal axis and exerting direct 
cytotoxicity. The most commonly used synthetic estrogen, 
DES, produces ≥50% PSA reduction in 26% to 66% of pa-
tients with CRPC [23,24]. However, its utility is limited due 
to thromboembolic toxicity, which was not mitigated by 
low-dose warfarin [25].
　Although adrenal androgens, such as dehydroepiandro-
sterone, dehydroepiandrosterone sulfate, and androsten-
edione, are weak androgens, they retain the potential to 
stimulate prostate cancer growth in the face of testicular 
androgen suppression [26]. Ketoconazole inhibits cyto-
chrome P-450 enzyme-mediated steroidogenesis in the 
testes and adrenal glands. After antiandrogen withdrawal 
in patients with CRPC, high-dose (1,200 mg/day) and low- 
dose (600 mg/day) ketoconazole resulted in ≥50% PSA re-
duction in 27% to 63% and 27% to 46% of patients, re-
spectively [16,27-30].
　Several new agents are also being investigated in pa-
tients with CRPC. MDV3100 is a pure androgen receptor 
antagonist that blocks androgen receptor nuclear trans-
location and DNA binding more effectively than do the cur-
rently used androgen receptor antagonists [31,32]. A phase 
I/II study of MDV3100 in patients with metastatic CRPC 
showed ≥50% PSA reduction in 56% of patients, and a me-
dian time to radiological progression of 47 weeks. The agent 
was well tolerated and the most common adverse event was 
fatigue, which generally resolved with dose reduction [32]. 
A phase III trial comparing MDV3100 versus placebo in pa-
tients with docetaxel-refractory CRPC is underway [10,32, 
33].
　Abiraterone acetate is a selective, irreversible, inhibitor 
of CYP17 essential for androgen biosynthesis. It is 10- to 
30-fold more potent than the nonselective inhibitor ketoco-
nazole [10,34]. An early phase I/II and a phase II study dem-
onstrated ≥50% PSA reduction in 67% and 51% of pa-
tients, with a median time to PSA progression of 225 days 
and 169 days in patients with chemotherapy-naïve and 
post-docetaxel CRPC, respectively [34,35]. In a phase II 
study of abiraterone acetate plus prednisone in patients 
with docetaxel-refractory CRPC, ≥50% PSA reduction 
was observed in 36% of patients, including 45% of ketocona-
zole-naïve and 26% of ketoconazole-pretreated patients, 
and the median time to PSA progression was 169 days [36]. 
An interim analysis of data from a phase III trial (COU- 
AA-301) comparing abiraterone acetate plus prednisone to 
prednisone alone in patients with docetaxel-refractory 
CRPC was recently presented at the 2010 meeting of the 
European Society for Medical Oncology (ESMO). Abirate-
rone therapy resulted in significant improvement in over-
all survival (OS), from 10.4 months to 14.8 months (p＜ 
0.0001). It also yielded significant improvement in time to 
PSA progression (10.2 months vs. 6.6 months; p＜0.0001), 
radiographic progression-free survival (PFS) (5.6 months 
vs. 3.6 months; p＜0.0001), and PSA response rate (29.1% 
vs. 5.5%; p＜0.0001) compared with placebo [37].
SYSTEMIC CHEMOTHERAPY
1. First-line chemotherapy
Prostate cancer was considered unresponsive to chemo-
therapy until the mid-1990s, when mitoxantrone in combi-
nation with prednisone was shown to play a role in the pal-
liative treatment of patients with CRPC [38-41]. A Canadian 
phase III study in patients with symptomatic CRPC dem-
onstrated that mitoxantrone plus prednisone resulted in 
significant improvement in palliative response (29% vs. 
12%; p=0.01) and duration of palliation (43 weeks vs. 18 
weeks; p＜0.0001) compared with prednisone alone [41]. 
The Cancer and Leukemia Group B (CALGB) study in pa-
tients with CRPC showed that mitoxantrone plus hydro-
cortisone delayed time to treatment failure and disease 
progression with no improvement in OS compared to hy-
drocortisone alone [42]. In a phase III US Oncology study 
in patients with asymptomatic CRPC, mitoxantrone plus 
prednisone achieved a significantly superior outcome in ≥
50% PSA reduction (48% vs. 24%; p=0.007), albeit with no Korean J Urol 2011;52:157-165
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difference in median time to treatment failure, median 
time to progression, or median survival compared to pre-
dnisone alone [43]. Taken together, the effect of mitoxan-
trone is palliative, with no improvement in OS. Mitoxan-
trone was approved by the US Food and Drug Administrat-
ion (FDA) for the palliative treatment of CRPC in 1996, and 
became the reference therapy for comparison against other 
regimens [38-40].
　In 2004, two randomized clinical trials, the TAX 327 and 
Southwest Oncology Group (SWOG) 99-16, demonstrated 
for the first time a survival advantage with docetax-
el-based chemotherapy compared to mitoxantrone in pa-
tients with metastatic CRPC [44,45].
　In the TAX 327 study, patients with metastatic CRPC 
were randomized to one of three treatment arms: 3-weekly 
docetaxel, docetaxel weekly for 5 out of every 6 weeks, or 
control therapy with 3-weekly mitoxantrone. In addition, 
patients also received oral prednisone daily. The study 
showed that the median survival of patients treated with 
3-weekly docetaxel was significantly longer than that of pa-
tients treated with mitoxantrone (18.9 months vs. 16.5 
months; p=0.009). Three-weekly docetaxel therapy also 
yielded significantly superior outcomes with respect to ≥
50% PSA reduction (45% vs. 32%; p＜0.001), pain reduction 
(35% vs. 22%; p=0.01), and improvement in quality of life 
(22% vs. 13%; p=0.009) compared to mitoxantrone [44].
　In the SWOG 99-16 study, patients with metastatic 
CRPC were randomized to docetaxel plus estramustine or 
mitoxantrone plus prednisone. Docetaxel plus estramus-
tine therapy resulted in significant improvement in me-
dian OS (17.5 months vs. 15.6 months; p=0.02), median 
time to progression (6.3 months vs. 3.2 months; p＜0.001), 
and ≥50% PSA reduction (50% vs. 27%; p＜0.001) [45].
　On the basis of these findings, docetaxel with prednisone 
therapy for the treatment of metastatic CRPC was ap-
proved by the US FDA in May 2004 and is now widely ac-
cepted as the standard of care for chemotherapy in patients 
with CRPC [38-40].
　Recently updated data from the TAX 327 study, obtained 
after extended follow-up, are consistent with previously re-
ported results. The median survival of patients treated 
with 3-weekly docetaxel was significantly longer than that 
of patients treated with mitoxantrone (19.2 months vs. 16.3 
months; p=0.004). More patients survived ≥3 years in the 
3-weekly docetaxel arm than in the mitoxantrone arm 
(18.6% vs. 13.5%) [46].
　Recently, docetaxel has also been combined with other 
agents to improve efficacy. Capecitabine is an oral fluo-
ropyrimidine preferentially converted to 5-fluorouracil by 
thymidine phosphorylase in tumor tissues [47-49]. A phase 
II trial of weekly docetaxel plus capecitabine in patients 
with CRPC demonstrated ≥50% PSA reduction in 68% to 
73% of patients, with a median OS of 17.7 to 22.0 months 
[47,48]. A phase II trial of 3-weekly docetaxel plus capecita-
bine in patients with CRPC resulted in ≥50% PSA reduc-
tion in 41% of patients, with a median survival of 17 months 
[49].
　Calcitriol (1,25-dihydroxycholecalciferol) is the bio-
logically active form of vitamin D [38]. A single-institution 
phase II study of docetaxel plus calcitriol in patients with 
metastatic CRPC demonstrated ≥50% PSA reduction in 
81% of patients, with a median time to progression and me-
dian survival of 11.4 months and 19.5 months, respectively. 
[50]. In the randomized phase II Androgen Independent 
Prostate Cancer Study of Calcitriol Enhancing Taxotere 
(ASCENT), patients with metastatic CRPC were random-
ized to docetaxel plus calcitriol (DN-101) or docetaxel 
monotherapy. Docetaxel plus calcitriol therapy did not 
show statistically significant improvement in ≥50% PSA 
reduction compared to docetaxel monotherapy (63% vs. 
52%; p=0.07), but multivariate analysis demonstrated a 
lower risk of death (hazard ratio 0.67, p=0.04) [51]. These 
results led to the initiation of the phase III ASCENT-2 
study comparing docetaxel plus calcitriol to docetaxel 
monotherapy. However, this study was closed early be-
cause of an unexpectedly higher death rate in the docetaxel 
plus calcitriol arm [38].
2. Second-line chemotherapy
Treatment options in patients with CRPC that progresses 
after docetaxel-based chemotherapy have been limited.
　For patients who initially respond to first-line docetax-
el-based chemotherapy, re-treatment with docetaxel can 
be considered [11,52,53]. In the study by Ansari et al, out 
of 42 patients with metastatic CRPC treated with docetaxel 
plus prednisone, 10 patients were re-treated with the same 
regimen as second-line chemotherapy for PSA progression. 
Of these 10 patients, 7 patients who initially experienced 
＞50% PSA reduction with first-line chemotherapy re-
sponded again with ＞50% PSA reduction with second-line 
chemotherapy without experiencing a significant increase 
in hematologic toxicity [52]. In a recently published multi-
center study, re-treatment with docetaxel for disease pro-
gression in patients who responded initially to first-line do-
cetaxel-based chemotherapy, but discontinued for reasons 
other than disease progression or unacceptable toxicity, re-
sulted in ≥50% PSA reduction in 48% of patients with a 
median OS of 16 months. Docetaxel was well tolerated in 
most patients with 6% grade 3-4 hematologic toxicity [53].
　Mitoxantrone can be considered as a second-line chemo-
therapy in patients with docetaxel-refractory CRPC, but 
has limited efficacy and poor tolerability. Mitoxantrone re-
sulted in ≥50% PSA reduction in 5.9% to 20% of patients, 
and a median PSA PFS of between 6.1 weeks and 3.2 
months [54-57]. Grade 3-4 neutropenia occurred in 63% of 
patients [56].
　Satraplatin is an orally bioavailable third-generation 
platinum compound [58,59]. In a phase III study in patients 
with metastatic CRPC as first-line chemotherapy, satra-
platin plus prednisone resulted in a significant increase in 
PFS (5.2 months vs. 2.5 months; p=0.023), albeit without 
a significant difference in median OS (14.9 months vs. 11.9 
months; p=0.579) compared to prednisone alone [59]. This 
might be due to the small sample size, because the trial was Korean J Urol 2011;52:157-165
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closed early by the trial sponsor after 50 of the planned 380 
patients were randomized [59,60]. However, the result 
from the phase III Satraplatin and Prednisone Against 
Refractory Cancer (SPARC) trial in patients with meta-
static CRPC progressing after prior chemotherapy also 
showed that satraplatin plus prednisone resulted in sig-
nificant improvement in PFS (11.1 weeks vs. 9.7 weeks; p＜ 
0.001), albeit without improvement in median OS (61.3 
weeks vs. 61.4 weeks; p=0.80) compared to prednisone 
alone [60].
　Cabazitaxel is a novel tubulin-binding taxane with anti-
tumor activity in docetaxel-refractory cancers [61-63]. In 
the randomized phase III Treatment of Hormone-Refractory 
Metastatic Prostate Cancer Previously Treated With a 
Taxotere-Containing Regimen (TROPIC) study, patients 
with metastatic CRPC who progressed during or after doce-
taxel-based chemotherapy were randomized to cabazitax-
el or mitoxantrone every 3 weeks. In addition, all patients 
received oral prednisone daily. Cabazitaxel therapy re-
sulted in improved median PFS (2.8 months vs. 1.4 months; 
p＜0.0001), median OS (15.1 months vs. 12.7 months), and 
lower risk of death (hazard ratio 0.70, p＜0.0001) compared 
to mitoxantrone. The most common grade 3-4 toxicity was 
neutropenia, which was observed in 82% of patients in the 
cabazitaxel arm and in 58% of patients in the mitoxantrone 
arm [64]. Cabazitaxel is the first chemotherapy shown to 
improve survival in patients with docetaxel-refractory 
metastatic CRPC. On this basis, it was approved for sec-
ond-line use in this setting by the US FDA in June 2010.
IMMUNOTHERAPY
Several immunotherapeutic agents for the treatment of 
prostate cancer have also been investigated.
　Sipuleucel-T is an autologous dendritic cell vaccine de-
signed to stimulate an immune response against prostate 
cancer. Sipuleucel-T consists of autologous peripheral 
blood mononuclear cells, including antigen-presenting 
cells (APCs), cultured with a recombinant fusion protein 
(PA2024) composed of prostatic acid phosphatase (PAP) 
linked to granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF) [10,65-67].
　The first phase III trial of sipuleucel-T (D9901) in pa-
tients with asymptomatic metastatic CRPC did not meet 
the primary endpoint of time to disease progression (11.7 
weeks for sipuleucel-T vs. 10.0 weeks for placebo; p=0.052), 
but demonstrated improvement in median OS (25.9 months 
for sipuleucel-T vs. 21.4 months for placebo; p=0.01) [65]. 
An identically designed phase III trial, D9902A, showed 
that the median time to disease progression and OS were 
not significantly different between sipuleucel-T and place-
bo, although the hazard ratios were in favor of sipuleucel-T 
[66].
　A subsequent phase III Immunotherapy for Prostate 
Adenocarcinoma Treatment (IMPACT) trial of sipuleucel- 
T in patients with asymptomatic or minimally sympto-
matic metastatic CRPC shared a similar design to the origi-
nal trial, but designated OS as the primary endpoint. 
Treatment with sipuleucel-T resulted in a 4.1-month im-
provement in median OS (25.8 months vs. 21.7 months), 
with a 22% relative reduction in the risk of death (hazard 
ratio 0.78, p=0.03) compared to placebo [67]. These data led 
to the approval of sipuleucel-T for the treatment of asymp-
tomatic or minimally symptomatic metastatic CRPC by 
the US FDA in April 2010 [11,63].
　GVAX is a cellular vaccine composed of two allogeneic 
prostate cancer cell lines (LNCaP and PC-3) that is genet-
ically modified to secrete GM-CSF. Phase I and II trials of 
this vaccine in patients with CRPC demonstrated clinical 
benefit with limited toxicity [68,69]. On the basis of these 
early results, two phase III trials, Vaccine Immunotherapy 
with Allogeneic prostate cancer cell Lines 1 and 2 (VITAL-1 
and VITAL-2), were initiated to compare GVAX with con-
ventional therapy for CRPC. In the VITAL-1 trial, GVAX 
was compared to docetaxel plus prednisone in patients 
with asymptomatic CRPC. This trial was closed pre-
maturely, when the unplanned futility analysis indicated 
a ＜30% chance of meeting its predefined primary endpoint 
of OS improvement. In the VITAL-2 trial, GVAX plus doce-
taxel was compared to docetaxel plus prednisone in pa-
tients with symptomatic CRPC. The VITAL-2 was also ter-
minated early, when an interim analysis revealed more 
deaths in the GVAX arm than in the control arm [10,70].
　PROSTVAC-VF is a cancer vaccine consisting of a re-
combinant vaccinia vector as a priming immunization with 
subsequent multiple booster vaccinations, using a re-
combinant fowlpox vector. Both vectors contain the trans-
genes for PSA and a triad of T-cell co-stimulatory molecules 
called TRICOM, including B7.1, intercellular adhesion 
molecule-1 (ICAM-1), and leukocyte function-associated 
antigen-3 (LFA-3) [70,71]. A phase I trial of PROSTVAC- 
VF in patients with CRPC showed PSA stabilization in 40% 
of patients and limited toxicity [72]. A phase II trial of 
PROSTVAC-VF in patients with minimally symptomatic 
metastatic CRPC did not meet the primary endpoint of 
PFS, but achieved an 8.5 month improvement in median 
OS (25.1 months for PROSTVAC-VF vs. 16.6 months for 
controls), and a 44% reduction in the death rate (hazard ra-
tio 0.56, p=0.0061) at 3 years post-study [73]. A phase III 
trial of PROSTVAC-VF is planned [70,73].
TARGETED THERAPY
1. Endothelin receptor antagonists
Atrasentan is a selective endothelin A (ETA) receptor an-
tagonist with an 1,800-fold greater affinity for ETA than 
ETB [74]. A phase III trial of atrasentan in patients with 
metastatic CRPC showed that atrasentan did not improve 
time to disease progression (hazard ratio 0.89, p=0.136) or 
OS (hazard ratio 0.97, p=0.775) compared to placebo [75]. 
The second phase III trial of atrasentan in patients with 
nonmetastatic CRPC demonstrated lengthening of PSA 
doubling time (p=0.031), and slowing of bone alkaline phos-
phatase increment (p＜0.001) compared to placebo, but did Korean J Urol 2011;52:157-165
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not meet the primary endpoint of time to disease pro-
gression (p=0.288) [76]. A phase III trial of docetaxel with 
or without atrasentan in patients with metastatic CRPC 
is ongoing [10,76].
　Zibotentan (ZD4054) is a specific ETA receptor antago-
nist with no detectable binding to the ETB receptor 
[74,77,78]. Recently, the final analysis of the phase II trial 
of zibotentan in patients with asymptomatic or mildly 
symptomatic metastatic CRPC was reported [77]. Consis-
tent with previous analyses [78], zibotentan therapy did 
not meet the primary endpoint of time to progression. 
Although the difference in OS between the zibotentan and 
placebo arms had decreased compared to the previous anal-
yses, zibotentan therapy continued to suggest an OS ad-
vantage (23.5 months for zibotentan 10 mg, 23.9 months 
for zibotentan 15 mg vs. 19.9 months for placebo; p=0.254, 
p=0.103, respectively) [77]. Three phase III Zibotentan 
Endothelin A Use (ENTHUSE) trials are ongoing in pa-
tients with CRPC [74].
2. Angiogenesis inhibitors
Bevacizumab is a recombinant humanized monoclonal an-
tibody with anti-angiogenic activity through blockade of 
vascular endothelial growth factor (VEGF) [79]. The phase 
II, CALGB 90006 study in chemotherapy-naïve metastatic 
CRPC patients showed that the combination of docetaxel, 
estramustine, and bevacizumab resulted in ＞50% PSA re-
duction in 75% of patients, and partial response in 59% of 
patients, with a median OS of 24 months [80]. In a phase 
II study in patients with docetaxel-refractory CRPC, bev-
acizumab plus docetaxel resulted in ≥50% PSA reduction 
in 55% of patients, and partial response in 37.5% of pa-
tients, with a median OS of 9 months [81]. In the phase III, 
CALGB 90401 study, chemotherapy-naïve metastatic 
CRPC patients were randomized to docetaxel plus pre-
dnisone in combination with either bevacizumab or placebo. 
The results were recently presented at the 2010 American 
Society of Clinical Oncology (ASCO) Annual Meeting, but 
disappointingly, the addition of bevacizumab to docetaxel 
plus prednisone did not improve median OS (22.6 months 
for the experimental arm vs. 21.5 months for the control 
arm; hazard ratio 0.91, p=0.181) [82].
　Thalidomide is also an angiogenesis inhibitor. In a phase 
II trial of thalidomide in patients with metastatic CRPC, 
≥50% PSA reduction was observed in 18% of patients 
treated with low-dose thalidomide (200 mg/day), but in 
none of the patients treated with high-dose thalidomide 
(1,200 mg/day) [83]. In a phase II trial comparing weekly 
docetaxel plus thalidomide versus docetaxel monotherapy 
in patients with metastatic CRPC, the addition of thalido-
mide resulted in a higher ≥50% PSA reduction rate (53% 
vs. 37%; p=0.32) and improvement in median OS (28.9 
months vs. 14.7 months; p=0.11) compared to docetaxel 
monotherapy [84].
　In a subsequent phase II trial in patients with metastatic 
CRPC, the efficacy of the combination of bevacizumab, tha-
lidomide, docetaxel, and prednisone was evaluated. The 
combination of these drugs resulted in ≥50% PSA reduc-
tion in 89.6% of patients, with a median time to progression 
and median OS of 18.3 months and 28.2 months, re-
spectively [85].
3. Tyrosine kinase inhibitors
Small molecule tyrosine kinase inhibitors (TKIs) have also 
been studied in prostate cancer.
　In the first stage of a phase II trial of sorafenib, 22 pa-
tients with metastatic CRPC were enrolled. Fifty-nine per-
cent of patients had received prior docetaxel or mitox-
antrone. Sorafenib therapy failed to show ＞50% PSA re-
duction. However, discordance between PSA progression 
and improvement in metastatic lesions on bone scan was 
observed in 2 patients [86]. In the second stage of the trial, 
24 additional patients with metastatic CRPC were enrolled. 
Eighty-eight percent of patients had received prior doce-
taxel. Of the 24 patients, 1 patient experienced partial re-
sponse and 10 patients attained stable disease. The me-
dian PFS and median OS were 3.7 months and 18.0 months, 
respectively. Pooled data from both stages of the trial for 
all 46 patients demonstrated a median OS of 18.3 months 
[87]. Another phase II study included 57 chemotherapy- 
naïve CRPC patients. Out of 55 evaluable patients, 2 pa-
tients experienced ＞50% PSA reduction and 15 patients 
attained stable disease (4 according to RECIST and 11 ac-
cording to PSA-based criteria) [88]. A third phase II trial 
that included 28 patients with chemotherapy-naïve CRPC 
showed ≥50% PSA reduction in 1 patient (3.6%). However, 
PSA reduction was observed in 10 out of 16 patients who 
discontinued sorafenib therapy, which suggested that sor-
afenib may affect PSA production or secretion indepen-
dently of its antitumor activity [89].
　A phase II study of sunitinib in patients with chemo-
therapy-naïve (n=17) or docetaxel-refractory (n=17) CRPC 
revealed ＞50% PSA reduction in 1 patient per treatment 
group. However, as for the patients in the sorafenib trial, 
assessments of radiologic disease status were often dis-
cordant with PSA changes [90]. Another phase II study of 
sunitinib in patients with metastatic CRPC whose disease 
progressed following one to two chemotherapy regimens, 
including docetaxel, showed that sunitinib therapy re-
sulted in ≥50% PSA reduction in 12.1% of patients, ≥30% 
reductions in the size of measurable disease by RECIST cri-
teria in 11.1% of patients, a reduction in pain score of ≥2 
points in 13.6% of patients, and a median PFS of 19.4 weeks. 
Severe grade 3-4 toxicities were infrequent, but drug dis-
continuation due to toxicities occurred in 52.8% of patients 
[91]. The phase I/II trial of sunitinib in combination with 
docetaxel and prednisone resulted in PSA response in 56% 
of patients, a median time to PSA progression of 42.1 
weeks, and a partial response of measurable disease in 39% 
of patients. The most common grade 3-4 adverse events 
were neutropenia (75%), febrile neutropenia (15%), and fa-
tigue (15%) [92]. A phase III trial comparing sunitinib plus 
prednisone versus prednisone alone in patients with doce-
taxel-refractory metastatic CRPC is underway. The pri-Korean J Urol 2011;52:157-165
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mary endpoint of this trial is OS [90,93].
CONCLUSIONS
The combination of docetaxel and prednisone is currently 
accepted as the standard first-line chemotherapy for pa-
tients with CRPC and has been approved by the US FDA. 
Recently, sipuleucel-T and cabazitaxel have been shown to 
improve OS in patients with asymptomatic or minimally 
symptomatic metastatic CRPC and in patients with doce-
taxel-refractory metastatic CRPC, respectively, and both 
drugs have been approved by the US FDA. However, the 
survival benefit of these drugs in CRPC is modest, and more 
efficacious drugs and drug combinations need to be developed. 
Although various agents appear promising for the treat-
ment of CRPC in early-phase clinical trials, adequately 
powered randomized phase III trials will be required to val-
idate these findings.
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